RenovoRx

RNXT · NASDAQ

$1.20+$0.04 (+3.45%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.16

RNXT analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $7.27 (+505.6% upside)

Low: $3.03
Now: $1.20
High: $15.23

Upgrades and downgrades

The latest rating actions, newest first

RNXT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Aug 28, 2026	Maintains	Buy	$14.00 → $14.50	28%
Ascendiant Capital	Jun 1, 2026	Maintains	Buy	$13.50 → $14.00	28%
Ascendiant Capital	Apr 9, 2026	Maintains	Buy	$13.00 → $13.50	28%
HC Wainwright & Co.	Apr 8, 2026	Maintains	Buy	$3.00	43%
Ascendiant Capital	Feb 17, 2026	Maintains	Buy	$12.50 → $13.00	28%
Ascendiant Capital	Nov 21, 2025	Maintains	Buy	$12.00 → $12.50	28%

The case for and against

Updated Oct 21, 2026

Bull case

RenovoRx is attractive fundamentally because it combines a cleared commercial product with a differentiated oncology platform: RenovoCath is gaining traction, with active centers rising from 5 in September 2025 to 16 currently and a path to 36 by the end of 2026, supporting projected revenue growth to $2.8 million in 2026 and $4.5 million in 2027. Its TAMP platform may offer a meaningful clinical advantage by delivering therapy directly to the tumor while potentially reducing toxicity versus systemic IV treatment, and the ongoing Phase III TIGeR-PaC trial gained confidence when the DMC recommended continuation after the second interim analysis in August 2025, following positive 1st interim analysis results in March 2023. Financially, the balance sheet is solid with $12 million in cash and no debt, plus $10 million raised in Q1, while enrollment is expected to finish in June 2026 with final data anticipated in mid to late 2027.

Bear case

RenovoRx is still a clinical-stage biotech with limited commercial traction, as fiscal Q1 2026 revenue was only $0.6 million and fiscal Q2 2026 revenue was $0.9 million, while pro forma EPS remained negative at $(0.08) and $(0.05), respectively. Despite strong year-over-year growth, the company provided no Q1 or Q2 guidance, underscoring how early and uncertain the business remains relative to the large pancreatic cancer opportunity it cites. The bearish view is driven by the explicit risks of balance sheet and liquidity pressure, clinical and regulatory setbacks, commercialization and reimbursement challenges, and intense biotech sentiment risk, all of which could limit value creation before meaningful scale is achieved.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.